- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02540395
Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation
Prospective Donor-specific Cellular Alloresponse Assessment for Immunosuppression Minimization in de Novo Renal Transplantation
Study Overview
Status
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Prague 4
-
Prague, Prague 4, Czechia, 14021
- Institut klinické a experimentální medicíny
-
-
-
-
-
Nantes, France, 44093
- Centre Hospitalier Universitaire de Nantes
-
-
-
-
-
Berlin, Germany, 13353
- Department Nephrology and BCRT, Charité Universitätsmedizin Berlin
-
Hamburg, Germany, 20246
- Universitätsklinikum Hamburg-Eppendorf
-
Regensburg, Germany
- Universitätsklinikum Regensburg
-
-
-
-
-
Amsterdam, Netherlands
- Academisch Medisch Centrum bij de Universiteit van Amsterdam
-
-
-
-
Barcelona
-
Hospitalet de Llobregat, Barcelona, Spain, 08907
- Hospital Universitari de Bellvitge
-
-
-
-
-
London, United Kingdom, SE1 9RT
- Guy's Hospital, Great Maze Pond
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women, age ≥18 years.
- Subject must be a recipient of a first renal transplant from a deceased or living donor.
- Subject must have a current documented PRA (Panel of reactive antibodies) <20% and no detectable anti-class I and II HLA (human leukocyte Antigens) antibodies by solid phase assay (Luminex®).
- Subject is willing to provide signed written informed consent.
- Women of Childbearing Potential (WOCBP) must be using a highly effective method of contraception (Pearl-Index < 1) to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea ≥ 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level > 35 mIU/mL]. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG (Human chorionic gonadotropin)) within 72 hours prior to the start of clinical trial.
Exclusion Criteria:
- Subjects undergoing renal transplant with a current documented PRA >20% and/or detectable anti-class I and II HLA antibodies by solid phase assay (Luminex®).
- CDC (complement dependent cytotoxicity) positive cross match.
- Subjects receiving an allograft from a donor older than 65 years with elevated creatinine levels and/or treated diabetes.
- Cold ischemia time (CIT) higher than 24h.
- Subjects with a prior solid organ transplant (SOT), including renal re-transplantation, or receiving a concurrent SOT.
- Patients previously treated with daclizumab or basiliximab.
Subjects with underlying renal disease of:
- Primary focal segmental glomerulosclerosis.
- Type I or II membranoproliferative glomerulonephritis
- Atypical Haemolytic uremic syndrome (HUS) / thrombotic thrombocytopenic purpura syndrome.
- Subject with Hepatitis B chronic infection and/or active infection by Hepatitis C virus (positive PCR (polymerase chain reaction result) at the moment of transplant.
- Subjects with known human immunodeficiency virus (HIV) infection.
- Patients with active systemic infection that requires the continued use of antibiotics.
- Patients with neoplasia except localized skin cancer receiving appropriate treatment.
- Patients with severe anemia (hemoglobin < 6g/dl), leucopenia (WBC (White blood cells) <2500/mm3), thrombocytopenia (platelets <80.000/mm3).
- Hemodynamically instable patients even if their hemoglobin level counts > 6 g/dl.
- Patients with intestinal pathology or severe diarrhoea that can hinder absorption according to medical criteria.
- Subjects with a known hypersensibility to any of the drugs used in this protocol.
- Subjects who have used any investigational drug within 30 days prior to enrolment in this clinical trial.
- WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period, women who are pregnant or breastfeeding or women with a positive pregnancy test on enrolment.
- Subjects who are legally detained in an official institution
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group A: Standard of care
Standard of care immunosuppressive regimen based on TAC (Prograf) (achieving 4-8ng/ml trough levels), MMF (Cellcept, Myfortic, Myfenax)(1gr bid) and steroids (6-methyl prednisolone, Urbason, Methypred) (according to KDIGO guidelines). All patients in group A recieve the tripple-drug IS as suggested by guidelines. In case of rejection the patients are treated with high dosage of Methypred and/or Thymoglobuline |
The study group A will receive Tacrolimus (for Group A) (Prograf) to achieve 4-8 ng/ml trough levels during all the duration of the study. Tacrolimus (for Group A) (Tacrolimus) capsules should generally be administered on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal, to achieve maximal absorption.
Other Names:
Mycophenolate mofetil (MMF) (Cellcept, Myfortic, Myfenax) (for Group A) will be administered orally to patients in group A at conventional doses (1gr/12h). For subjects who develop nausea, diarrhea, or other Mycophenolate mofetil (MMF) (for Group A) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to Mycophenolate mofetil (MMF) (for Group A), the Mycophenolate mofetil (MMF) (for Group A) dose may be decreased to the maximally tolerated dose. Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™). The first dose of Mycophenolate mofetil (MMF) (for Group A) should be administered before transplantation.
Other Names:
At the time of surgery, all patients will receive 500 mg of 6-methyl prednisolone (steroids for Group A). Patients in arm A will receive 20 mg/day of 6-methyl prednisolone (steroids for Group A) (or the equivalent) during the first 2 weeks after transplantation, then tapering to 15 mg from week 3 to week 4 to finally be maintained at 5mg/day.
Other Names:
|
Experimental: Group B: "Low" Immunosuppression regimen
(based on TAC monotherapy (Prograf) to achieve 8-10 ng/ml trough levels during the first 4 weeks after transplantation and 6-8 ng/ml thereafter, MMF (Cellcept, Myfortic, Myfenax) (1g bid) during the first 7 days post-transplant and stopped thereafter) and steroids (6-methyl prednisolone; Urbason, Methypred) (tapering until discontinuation on month 2 post-transplant). In contrast to Group A the patients are treated with a two drug IS combination consisting of Prograf and Methypred. In case of rejection the patients are treated with hifg dosage of Methypred and/or Thymoglobuline. |
Tacrolimus (for Group B) will be administered orally twice a day (bid).
Tacrolimus (for Group B) will be initially given at the 0,1mg/kg bid to achieve a stable 12-hour trough level of 8-10 ng/mL during the first month after transplantation to progressively tapper to 6-8ng/ml thereafter.
Other Names:
MMF (mycophenolate mofetil) will be administered orally to patients in group B at conventional doses (1gr/12h) before transplant procedure and during the first 7 days after transplant. For subjects who develop nausea, diarrhea, or other MMF(mycophenolate mofetil) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to MMF), the MMF(mycophenolate mofetil) dose may be decreased to the maximally tolerated dose. Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™) or to Myfenax. From day 8 on, patients will not receive MMF.
Other Names:
At the time of surgery, all patients will receive 500mg of 6-methyl prednisolone (Steroids, Urbason, Methypred). Patients in group B will receive 250mg of 6-methyl prednisolone (or equivalent) on day 2, 125 mg on day 3, 60 mg on day 4 and 30 mg on day 5. From day 6 on, patients will receive 0.25 mg/kg/d of 6-methyl-prednisolone (Steroids, Urbason, Methypred) until month 1, then tapering until discontinuation on month 2 will be performed.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
assessment of anti-donor T-cell alloresponses using the IFN-γ ELISPOT test
Time Frame: 6 months
|
Patients with a positive anti-donor IFN-γ ELISPOT assay result (>25 spots/300.000 PBMC (peripheral blood mononuclear cells )) will be ruled out of the study and patients with negative anti-donor IFN-γ ELISPOT test (<25 spots/300.000 PBMC) will be randomized in 2 different groups (1:1). The main objective of the study is to demonstrate the utility and safety of the IFN-γ ELISPOT marker for the stratification of kidney transplant recipients into low and high IS regimens. |
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Differences across Treatment arms in eGFR (estimated glomerular Filtration rate) (ml/min)
Time Frame: after 3, 6 and 12 months
|
after 3, 6 and 12 months
|
Differences across Treatment arms in Biopsy proven acute rejection rate (BPAR rate)
Time Frame: after 6 and 12 months
|
after 6 and 12 months
|
Differences across Treatment arms in subclinical rejection rate using renal allograft biopsy
Time Frame: after 3 and 12 months
|
after 3 and 12 months
|
Differences across Treatment arms in Prevalence of death, and graft loss
Time Frame: after 6 and 12 months
|
after 6 and 12 months
|
Differences across Treatment arms in Prevalence of metabolic and cardiovascular co-morbidity (new onset diabetes mellitus (NODAT, dyslipidaemias, hypertension)
Time Frame: 12 months
|
12 months
|
Differences across Treatment arms in Prevalence of subjects that remain MMF and steroid-free
Time Frame: after 6 and 12 months
|
after 6 and 12 months
|
Differences across Treatment arms in Prevalence of Acute and chronic histologic lesions assessed by the Bannf'11 score in protocol biopsies
Time Frame: after 3 and 12 months
|
after 3 and 12 months
|
Differences across Treatment arms in Prevalence of patients that remain on Therapy
Time Frame: after 12 months
|
after 12 months
|
Differences across Treatment arms in Distribution of patients in distinct chronic kidney diseases (CKD) stages
Time Frame: after 12 months
|
after 12 months
|
Differences across Treatment arms in treatment cost (cost/benefit)
Time Frame: after 1,3,6,12 and 24 months
|
after 1,3,6,12 and 24 months
|
Differences across Treatment arms in development of a Panel reactive T (PRT)-cell response platform to evaluate general anti-HLA T-cell Responses using ELISPOT
Time Frame: at pre-transplantation, 3, 6 and 12 months after transplantation as well as at time of BPAR
|
at pre-transplantation, 3, 6 and 12 months after transplantation as well as at time of BPAR
|
Differences across Treatment arms in assessment of anti-donor and anti-HLA antibodies by Solid phase assays (Luminex®) and B-cell ELISPOT
Time Frame: at pre-transplantation, 3, 6 and 12 months after transplantation as well as at time of BPAR
|
at pre-transplantation, 3, 6 and 12 months after transplantation as well as at time of BPAR
|
Differences across Treatment arms in different viral load (CMV, EBV, BKV)
Time Frame: at months 1, 2, 3, 6 and 12 after transplantation
|
at months 1, 2, 3, 6 and 12 after transplantation
|
Differences across Treatment arms in study of virus-specific T-cell responses (ELISPOT)
Time Frame: at at pre-transplantation, 3, 6 and 12 after transplantation
|
at at pre-transplantation, 3, 6 and 12 after transplantation
|
Differences across Treatment arms in prevalence of transcriptional genes by RT-PCR in PBMC (peripheral blood mononuclear cells )
Time Frame: at pre-transplantation and months 1, 3, 6 and 12 after transplantation as well as at time of BPAR
|
at pre-transplantation and months 1, 3, 6 and 12 after transplantation as well as at time of BPAR
|
Differences across Treatment arms in flow cytometry assessment of peripheral blood mononuclear cells (PBMC)
Time Frame: at pre-transplantation and months 1, 3, 6 and 12 after transplantation as well as at time of BPAR
|
at pre-transplantation and months 1, 3, 6 and 12 after transplantation as well as at time of BPAR
|
Differences across Treatment arms in Quantitative analyses of urinary IP-10 (Interferon Gamma induced Protein)
Time Frame: at 4 weeks and at 3, 6 and 12 month after transplantation as well as at time of BPAR
|
at 4 weeks and at 3, 6 and 12 month after transplantation as well as at time of BPAR
|
Differences across Treatment arms in Assessment of protocol biopsies
Time Frame: at month 3 and 12 after transplantation
|
at month 3 and 12 after transplantation
|
Differences across Treatment arms in MicroRNA assessment in sera and urine
Time Frame: at pre-transplantation and months 1, 3, 6 and 12 after transplantation
|
at pre-transplantation and months 1, 3, 6 and 12 after transplantation
|
Differences across Treatment arms in evaluation of FOXP3 (Forkhead box P3) methylation degree at the TSDR (Treg-specific demethylated Region)
Time Frame: at pre-transplantation and months 1, 3, 6 and 12 after transplantation as well as at time of rejection
|
at pre-transplantation and months 1, 3, 6 and 12 after transplantation as well as at time of rejection
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Josep M. Grinyó, Prof. Dr., Renal Transplant Unit, Department Nephrology Bellvitge Universitari Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antitubercular Agents
- Antibiotics, Antitubercular
- Calcineurin Inhibitors
- Prednisolone
- Methylprednisolone Acetate
- Methylprednisolone
- Methylprednisolone Hemisuccinate
- Prednisolone acetate
- Prednisolone hemisuccinate
- Prednisolone phosphate
- Tacrolimus
- Mycophenolic Acid
Other Study ID Numbers
- CELLIMIN
- 2014-001325-33 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Disorder Related to Renal Transplantation
-
Ajou University School of MedicineCompletedDisorder Related to Renal TransplantationKorea, Republic of
-
University Hospital FreiburgRoche Pharma AG; Genzyme, a Sanofi Company; Astellas Pharma GmbHCompletedDisorder Related to Renal TransplantationGermany
-
Centre Hospitalier Universitaire de BesanconUnknownDisorder Related to Renal TransplantationFrance
-
Bristol-Myers SquibbCompletedDisorder Related to Renal TransplantationItaly, United States, Spain
-
Hospital Universitário São JoséUnknownDisorder Related to Renal TransplantationBrazil
-
Centre Hospitalier Universitaire de BesanconCompletedDisorder Related to Renal TransplantationFrance
-
Ajou University School of MedicineUnknownDisorder Related to Renal TransplantationKorea, Republic of
-
Centre Hospitalier Universitaire de BesanconUniversity Hospital, Lille; University Hospital, ToursRecruitingCancer | Disorder Related to Renal TransplantationFrance
-
Josep M CruzadoTerminatedMuscle Strength | Disorder Related to Renal Transplantation | Exercise, AerobicSpain
-
University of Illinois at ChicagoVeloxis PharmaceuticalsCompletedDisorder Related to Renal TransplantationUnited States
Clinical Trials on Tacrolimus (for Group A)
-
Mona Mohamed AbdelkhalekRecruiting
-
Abbott Medical DevicesCompleted
-
Cairo UniversityUnknownSingeleton Conceived Fresh and Frozen Embryo Transfer (ICSI/IVF), Naturally ConceivedEgypt
-
University of PaviaCompleted
-
Pontificia Universidade Católica do Rio Grande...Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.Not yet recruitingFrailty | Aging | Physical Disability
-
Kendall Healthcare Group, Ltd.Florida International UniversityUnknown
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...WithdrawnAcute Lymphoblastic Leukemia | Non-hodgkin LymphomaUnited States
-
Riphah International UniversityCompletedSacroiliac DisorderPakistan
-
King's College LondonKing Saud UniversityCompleted
-
ISPA - Instituto Universitario de Ciencias Psicologicas...Fundação para a Ciência e a TecnologiaCompletedPhysical Activity | Weight Loss | Eating Behavior | Behavior and Behavior Mechanisms | Self Esteem | Subjective Well-beingPortugal